AB375
/ Arcus Biosciences
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 10, 2023
Arcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline Update
(Yahoo News)
- "Arcus expects to advance its first candidate against an inflammation target, AB375, a highly selective KIT inhibitor, into the clinic in early 2024."
New trial • Immunology • Inflammation
1 to 1
Of
1
Go to page
1